Literature DB >> 7730473

The leukaemic phase of non-Hodgkin's lymphoma.

B J Bain1, D Catovsky.   

Abstract

Entities:  

Mesh：

Year:  1995        PMID： 7730473      PMCID： PMC502432          DOI： 10.1136/jcp.48.3.189

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  34 in total

1.  Follicular lymphoma; a re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases.

Authors:  E B HICKS; H RAPPAPORT; W J WINTER
Journal:  Cancer       Date:  1956 Jul-Aug       Impact factor: 6.860

2.  Diagnostic and prognostic significance of Sézary cells in peripheral blood smears from patients with cutaneous T cell lymphoma.

Authors:  E C Vonderheid; E L Sobel; P C Nowell; J B Finan; M K Helfrich; D S Whipple
Journal:  Blood       Date:  1985-08       Impact factor: 22.113

3.  Malignant lymphoma, well differentiated lymphocytic: its relationship with chronic lymphocytic leukemia and macroglobulinemia of Waldenström.

Authors:  G A Pangalis; B N Nathwani; H Rappaport
Journal:  Cancer       Date:  1977-03       Impact factor: 6.860

4.  Follicular lymphoma: A survey of 75 cases with special reference to the syndrome resembling chronic lymphocytic leukaemia.

Authors:  S Spiro; D A Galton; E Wiltshaw; R C Lohmann
Journal:  Br J Cancer Suppl       Date:  1975-03

5.  Follicular lymphoma: prognostic factors for response and survival.

Authors:  C J Gallagher; W M Gregory; A E Jones; A G Stansfeld; M A Richards; H S Dhaliwal; J S Malpas; T A Lister
Journal:  J Clin Oncol       Date:  1986-10       Impact factor: 44.544

6.  Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse.

Authors:  S H Swerdlow; J A Habeshaw; L J Murray; H S Dhaliwal; T A Lister; A G Stansfeld
Journal:  Am J Pathol       Date:  1983-11       Impact factor: 4.307

7.  Bone marrow histology in Waldenström's macroglobulinaemia. Clinical relevance of subtype recognition.

Authors:  R Bartl; B Frisch; G Mahl; R Burkhardt; A Fateh-Moghadam; R Pappenberger; W Sommerfeld; G Hoffmann-Fezer
Journal:  Scand J Haematol       Date:  1983-10

8.  Non-Hodgkin's lymphomas in leukemic phase: clinicopathologic correlations.

Authors:  S E Come; E S Jaffe; J C Andersen; R B Mann; B L Johnson; V T DeVita; R C Young
Journal:  Am J Med       Date:  1980-11       Impact factor: 4.965

9.  Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma.

Authors:  G P Schechter; E A Sausville; A B Fischmann; F Soehnlen; J Eddy; M Matthews; A Gazdar; J Guccion; D Munson; R Makuch
Journal:  Blood       Date:  1987-03       Impact factor: 22.113

10.  Malignant lymphoma, intermediate lymphocytic type: a clinicopathologic study of 42 cases.

Authors:  D D Weisenburger; B N Nathwani; L W Diamond; C D Winberg; H Rappaport
Journal:  Cancer       Date:  1981-09-15       Impact factor: 6.860
View more
  10 in total

Review 1.  Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.

Authors:  Philip A Thompson; William G Wierda
Journal:  Blood       Date:  2015-11-17       Impact factor: 22.113

2.  Frequency of hematologic malignancies in the population of Arica, Chile.

Authors:  Gloria Baeza Pérez; Gloria M Calaf; María Teresa Montalvo Villalba; Katherine Salgado Prieto; Fresia Caba Burgos
Journal:  Oncol Lett       Date:  2019-09-12       Impact factor: 2.967

3.  Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.

Authors:  David M Kurtz; Michael R Green; Scott V Bratman; Florian Scherer; Chih Long Liu; Christian A Kunder; Kazuhiro Takahashi; Cynthia Glover; Colm Keane; Shingo Kihira; Brendan Visser; Jason Callahan; Katherine A Kong; Malek Faham; Karen S Corbelli; David Miklos; Ranjana H Advani; Ronald Levy; Rodney J Hicks; Mark Hertzberg; Robert S Ohgami; Maher K Gandhi; Maximilian Diehn; Ash A Alizadeh
Journal:  Blood       Date:  2015-04-17       Impact factor: 22.113

Review 4.  Routine and specialised techniques in the diagnosis of haematological neoplasms.

Authors:  B J Bain
Journal:  J Clin Pathol       Date:  1995-06       Impact factor: 3.411

5.  MYC-Positive Diffuse Large B-Cell Lymphoma in Leukemic Phase at Presentation: A Diagnostic and Therapeutic Challenge.

Authors:  Yavuz Memis Bilgin; Rob Castel
Journal:  J Hematol       Date:  2021-04-27

6.  Bone marrow large B cell lymphoma bearing cyclin D3 expression: clinical, morphologic, immunophenotypic, and genotypic analyses of seven patients.

Authors:  Jyuri Watanuki; Kinta Hatakeyama; Takashi Sonoki; Hiro Tatetsu; Katsuhiko Yoshida; Soichiro Fujii; Minoru Mizutani; Toru Abo; Miwa Kurimoto; Hiroshi Matsuoka; Fumihiko Matsuno; Hideki Nakakuma
Journal:  Int J Hematol       Date:  2009-07-29       Impact factor: 2.490

7.  Distribution and features of hematological malignancies in Eastern Morocco: a retrospective multicenter study over 5 years.

Authors:  Mounia Elidrissi Errahhali; Manal Elidrissi Errahhali; Redouane Boulouiz; Meryem Ouarzane; Mohammed Bellaoui
Journal:  BMC Cancer       Date:  2016-02-25       Impact factor: 4.430

8.  Infiltrative Rash Secondary to Leukemic-Phase Diffuse Large B-Cell Lymphoma With t(14;18), CDKN2A and MLL Deletion.

Authors:  Iris Y Sheng; Diana O Treaba; Kenneth D Bishop
Journal:  J Hematol (Brossard)       Date:  2017-09-20

9.  Rare but Potentially Fatal Presentations of Diffuse Large B-cell Lymphoma: Leukemic Phase or Hemophagocytic Syndrome in Bone Marrow.

Authors:  Wan Awatif Wan Mohd Zohdi; Ahmad Zulhimi Ismail; Nurasyikin Yusof; Azlin Ithnin; Salwati Shuib; Noraidah Masir; Sivakumar Palaniappan; Nor Rafeah Tumian
Journal:  Clin Pathol       Date:  2022-01-09

10.  Diffuse large B-cell lymphoma presenting in the leukemic phase.

Authors:  Patricia Puccetti Pires; Marcia Yoshie Kanegae; Jairo Rays; Marcos Catania; Fabiana Roberto Lima; Thiago Rodrigo Noronha; Andre Neder Ramires Abdo; Juliana Pereira
Journal:  Autops Case Rep       Date:  2016-03-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.